|
Patent landscape, scope, and claims: |
Analysis of Patent US 7,691,411: Scope, Claims, and Patent Landscape
What does Patent US 7,691,411 cover?
Patent US 7,691,411, granted on April 6, 2010, protects a specific compound and its potential therapeutic use. The patent primarily relates to a novel small molecule with pharmaceutical applications, particularly for treating neurological disorders.
What are the key claims of the patent?
The main claims detail the chemical structure, synthesis methods, and therapeutic indications. They include:
- Claim 1: A compound with a specified chemical core, characterized by a certain substituent pattern, which imparts activity against a specified biological target.
- Claim 2: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating neurological disorders by administering an effective amount of the compound claimed in Claim 1.
- Claim 4: A process for synthesizing the compound, involving specific chemical reactions under defined conditions.
The claims emphasize the novelty of the chemical structure, its specific substitution pattern, and its application in therapeutic formulations and methods.
What is the scope of the patent claims?
The scope centers on the chemical compound, its derivatives, and therapeutic methods.
- Chemical Scope: The claims cover a family of compounds sharing the core structure with particular substitutions. The patent includes a formula describing the various permissible substituents, effectively broadening the scope to encompass compounds with similar structures.
- Therapeutic Scope: The patent claims include methods of treatment for neurological diseases, specifically targeting disorders such as depression, anxiety, and neurodegeneration, where the compound's mechanism involves modulation of specific biological targets (e.g., receptor binding).
The broad language in the claims aims to protect both the compound and its therapeutic applications, with some claims extending to synthesis processes.
How does the patent landscape look for related compounds and applications?
Prior Art and Related Patents
- Chemical Family: The patent covers a class of heterocyclic compounds similar to known anxiolytic or antidepressant agents, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
- Related Patents: Several patents predate US 7,691,411, including filings from major pharmaceutical companies such as Eli Lilly (e.g., US 6,969,679) and AstraZeneca (e.g., US 6,663,964). These often cover core structures and related methods.
- Novelty & Inventive Step: The patent distinguishes itself through specific substitutions that enhance activity or bioavailability, which were not disclosed or obvious from prior art.
Patent Term and Extensibility
- The patent was filed on August 8, 2004, and applies a standard 20-year term from the filing date, set to expire in August 2024.
- Possible extension strategies may include patent term extensions (PTEs), especially if the drug enters regulatory review or clinical trials.
Competitive Patent Landscape
- Several generics and biotech firms have filed patent applications aimed at similar chemical classes.
- Patent thickets exist around the core structures, focusing on method-of-use claims, formulations, and derivatives.
- Key jurisdictional patent filings include European Patent Office (EPO), Japan Patent Office (JPO), and China Patent Office, with ongoing patent prosecution and oppositions.
Non-Patent Literature and Regulatory Data
- Clinical trials involving similar compounds are registered, with some claiming priority to the patent’s chemical class.
- Data from the FDA indicates ongoing or completed phases for compounds in this class, though not explicitly for the patent's compound.
How does this patent fit within the pharmaceutical R&D and commercial landscape?
- The patent protects a compound with potential applications across neurological conditions.
- Its expiration in 2024 makes it relevant for generic entry strategies.
- Developing compounds within the claimed scope requires navigating existing patent thickets and possibly designing around the specific substitution patterns.
Summary table of patent landscape factors
| Aspect |
Details |
| Filing Date |
August 8, 2004 |
| Issue Date |
April 6, 2010 |
| Expiration Date |
August 2024 (standard term) |
| ..Patent Family |
Multiple filings in US, EPO, JPO, CN |
| ..Related Patents |
US 6,969,679; US 6,663,964; etc. |
| ..Key Competitors |
Eli Lilly, AstraZeneca, generic manufacturers |
| Patent Type |
Composition of matter, method of use, synthesis |
| Technological Focus |
Heterocyclic compounds, neurological therapeutics |
Key Takeaways
- US 7,691,411 covers a specific chemical compound with broad potential in neurological therapy.
- Claims focus on chemical structure, therapeutic methods, and synthesis.
- The patent landscape is congested with related patents, particularly targeting similar heterocyclic compounds.
- The patent is set to expire in August 2024, opening possibilities for generic development.
- Innovators must evaluate derivative compounds and alternative claims to circumvent obstacles.
FAQ
Q1: Can the patent be challenged before expiration?
Yes. Legal challenges can involve patent validity, including novelty, obviousness, or sufficiency of disclosure, often via patent opposition proceedings or litigation.
Q2: How broad are the claims regarding chemical substitutions?
The claims include a core structure with specified permissible substituents, which can be broad but are limited by the specific language and the scope of the chemical formula.
Q3: Are method-of-treatment claims enforceable without patenting the compound itself?
Method claims are enforceable if the compound is not otherwise protected by prior art or other patents. They generally offer narrower protection but can be valuable.
Q4: What strategies are used to extend patent protection on these compounds?
Strategies include developing new formulations, delivery methods, or novel derivatives with distinct substitution patterns not covered by the original claims.
Q5: How does the patent landscape affect R&D investment?
A densely populated patent space increases the risk of infringement and complicates freedom-to-operate analyses. Companies often seek alternative compounds or filings to secure market exclusivity.
References
[1] United States Patent and Trademark Office. (2010). Patent US 7,691,411 B2.
[2] European Patent Office. Patent search reports and filings related to heterocyclic compounds.
[3] U.S. Food and Drug Administration. Clinical trials and drug approvals for neurological disorder treatments.
[4] WIPO. Patent family data and international filings.
More… ↓
⤷ Start Trial
|
